Dipeptidyl peptidase‐4 inhibitors are effective in Japanese type 2 diabetic patients with sustained endogenous insulin‐secreting capacity, a higher body mass index and insulin resistance

Recently, dipeptidyl peptidase‐4 (DPP‐4) inhibitors have become available in Japan. It has not yet been clarified what clinical parameters could discriminate DPP‐4 inhibitor‐effective patients from DPP‐4 inhibitor‐ineffective patients.

[1]  Weiping Jia,et al.  Diabetes in Asia: epidemiology, risk factors, and pathophysiology. , 2009, JAMA.

[2]  Y. Seino,et al.  Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. , 2004, Metabolism: clinical and experimental.

[3]  T. Funahashi,et al.  Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin‐secreting capacity , 2011, Journal of diabetes investigation.

[4]  J. Shaw,et al.  Global and societal implications of the diabetes epidemic , 2001, Nature.

[5]  H. Kanehara,et al.  Obesity may attenuate the HbA1c‐lowering effect of sitagliptin in Japanese type 2 diabetic patients , 2011, Journal of diabetes investigation.

[6]  Y. M. Cho,et al.  New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser , 2011, Diabetologia.

[7]  G. Striker.  Glucose toxicity. , 2001, Kidney International.

[8]  Akihisa Imagawa,et al.  Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes. , 2010, Biochemical and biophysical research communications.

[9]  T. Sanke,et al.  Prevalence of metabolic syndrome in Japanese type 2 diabetic patients and its significance for chronic vascular complications. , 2008, Diabetes research and clinical practice.

[10]  T. Funahashi,et al.  Metabolic syndrome: Clinical concept and molecular basis , 2007, Annals of medicine.

[11]  Y. Terauchi,et al.  The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. , 2012, Diabetes research and clinical practice.

[12]  Mitsutoshi Kato,et al.  Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. , 2009, Diabetes research and clinical practice.

[13]  R. DeFronzo,et al.  Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control , 2008, Diabetes Care.

[14]  Xiao Wang,et al.  Early insulin secretion failure leads to diabetes in Chinese subjects with impaired glucose regulation , 2009, Diabetes/metabolism research and reviews.

[15]  Yuichiro Yamada,et al.  Factors responsible for age-related elevation in fasting plasma glucose: a cross-sectional study in Japanese men. , 2008, Metabolism: clinical and experimental.

[16]  T. Yanase,et al.  Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. , 2012, Diabetes research and clinical practice.